Myocardial ischemia reperfusion injury: From basic science to clinical bedside

Seminars in Cardiothoracic and Vascular Anesthesia

Volumn 16, Issue 3, 2012, Pages 123-132

  Frank, Anja ^a,b   Bonney, Megan ^a   Bonney, Stephanie ^a   Weitzel, Lindsay ^a   Koeppen, Michael ^a,c   Eckle, Tobias ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

heart; ischemic reperfusion injury; myocardial infarction; reperfusion injury; therapeutic impact

Indexed keywords

MITOCHONDRIAL PERMEABILITY TRANSITION PORE; RANOLAZINE; TRIMETAZIDINE;

ACUTE HEART INFARCTION; FATTY ACID METABOLISM; GLUCOSE METABOLISM; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HUMAN; INFLAMMATION; ISCHEMIC POSTCONDITIONING; ISCHEMIC PRECONDITIONING; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL PERMEABILITY; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PATHOPHYSIOLOGY; REPERFUSION INJURY; REVIEW; STABLE ANGINA PECTORIS; UNSTABLE ANGINA PECTORIS;

ANIMALS; DISEASE MODELS, ANIMAL; FIBRINOLYTIC AGENTS; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; PERCUTANEOUS CORONARY INTERVENTION;

EID: 84871806998     PISSN: 10892532     EISSN: 19405596     Source Type: Journal    
DOI: 10.1177/1089253211436350     Document Type: Review

References (75)

1. Turer AT, Hill JA. Pathogenesis of myocardial ischemia-reperfusion injury and rationale for therapy. Am J Cardiol. 2010 ; 106: 360-368
2. Jennings RB, Sommers HM, Smyth GA, Flack HA, Linn H. Myocardial necrosis induced by temporary occlusion of a coronary artery in the dog. Arch Pathol. 1960 ; 70: 68-78
3. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986 ; 74: 1124-1136
4. Kloner RA, Bolli R, Marban E, Reinlib L, Braunwald E. Medical and cellular implications of stunning, hibernation, and preconditioning: an NHLBI workshop. Circulation ; 1998 ; 1998. 1848.
5. Jennings RB, Reimer KA. The cell biology of acute myocardial ischemia. Annu Rev Med. 1991 ; 42: 225-246
6. Kloner RA, Jennings RB. Consequences of brief ischemia: stunning, preconditioning, and their clinical implications: part 2. Circulation. 2001 ; 104: 3158-3167
7. Kloner RA, Jennings RB. Consequences of brief ischemia: stunning, preconditioning, and their clinical implications: part 1. Circulation. 2001 ; 104: 2981-2989
8. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007 ; 357: 1121-1135
9. Jaswal JS, Keung W, Wang W, Ussher JR, Lopaschuk GD. Targeting fatty acid and carbohydrate oxidation: a novel therapeutic intervention in the ischemic and failing heart. Biochim Biophys Acta. 2011 ; 1813: 1333-1350
10. Lopaschuk GD. AMP-activated protein kinase control of energy metabolism in the ischemic heart. Int J Obes (Lond). 2008 ; 32 (suppl 4). S29 - S35
11. Lopaschuk GD, Stanley WC. Malonyl-CoA decarboxylase inhibition as a novel approach to treat ischemic heart disease. Cardiovasc Drugs Ther. 2006 ; 20: 433-439
12. Heusch G, Boengler K, Schulz R. Inhibition of mitochondrial permeability transition pore opening: the Holy Grail of cardioprotection. Basic Res Cardiol. 2010 ; 105: 151-154
13. Halestrap AP, Pasdois P. The role of the mitochondrial permeability transition pore in heart disease. Biochim Biophys Acta. 2009 ; 1787: 1402-1415
14. Cadenas S, Aragones J, Landazuri MO. Mitochondrial reprogramming through cardiac oxygen sensors in ischaemic heart disease. Cardiovasc Res. 2010 ; 88: 219-228
15. Cain BS, Meldrum DR, Dinarello CA, et al. Tumor necrosis factor-alpha and interleukin-1beta synergistically depress human myocardial function. Crit Care Med. 1999 ; 27: 1309-1318
16. Kleinbongard P, Schulz R, Heusch G. TNFalpha in myocardial ischemia/reperfusion, remodeling and heart failure. Heart Fail Rev. 2011 ; 16: 49-69
17. Kawaguchi M, Takahashi M, Hata T, et al. Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. Circulation. 2011 ; 123: 594-604
18. Arslan F, de Kleijn DP, Pasterkamp G. Innate immune signaling in cardiac ischemia. Nat Rev Cardiol. 2011 ; 8: 292-300
19. Fragasso G, Salerno A, Lattuada G, et al. Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure. Heart. 2011 ; 97: 1495-1500
20. Horowitz JD, Chirkov YY, Kennedy JA, Sverdlov AL. Modulation of myocardial metabolism: an emerging therapeutic principle. Curr Opin Cardiol. 2010 ; 25: 329-334
21. Gao D, Ning N, Niu X, Hao G, Meng Z. Trimetazidine: a meta-analysis of randomised controlled trials in heart failure. Heart. 2011 ; 97: 278-286
22. Ashrafian H, Neubauer S. Metabolic modulation in heart failure: high time for a definitive clinical trial. Heart. 2011 ; 97: 267-268
23. Ko HJ, Zhang Z, Jung DY, et al. Nutrient stress activates inflammation and reduces glucose metabolism by suppressing AMP-activated protein kinase in the heart. Diabetes. 2009 ; 58: 2536-2546
24. Tomai F. Warm up phenomenon and preconditioning in clinical practice. Heart. 2002 ; 87: 99-100
25. Tapuria N, Kumar Y, Habib MM, Abu Amara M, Seifalian AM, Davidson BR. Remote ischemic preconditioning: a novel protective method from ischemia reperfusion injury-a review. J Surg Res. 2008 ; 150: 304-330
26. Bein B, Meybohm P. Organ protection by conditioning [in German]. Anasthesiol Intensivmed Notfallmed Schmerzther. 2010 ; 45: 254-262
27. Tocchetti CG, Stanley BA, Murray CI, et al. Playing with cardiac "redox switches": the "HNO way" to modulate cardiac function. Antioxid Redox Signal. 2011 ; 14: 1687-1698
28. Sinha SS, Shiva S, Gladwin MT. Myocardial protection by nitrite: evidence that this reperfusion therapeutic will not be lost in translation. Trends Cardiovasc Med. 2008 ; 18: 163-172
29. Zhao ZQ, Corvera JS, Halkos ME, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol. 2003 ; 285: H579 - H588
30. Thibault H, Piot C, Staat P, et al. Long-term benefit of postconditioning. Circulation. 2008 ; 117: 1037-1044
31. Xue F, Yang X, Zhang B, et al. Postconditioning the human heart in percutaneous coronary intervention. Clin Cardiol. 2010 ; 33: 439-444
32. Jin ZX, Zhou JJ, Xin M, et al. Postconditioning the human heart with adenosine in heart valve replacement surgery. Ann Thorac Surg. 2007 ; 83: 2066-2072
33. Darling CE, Solari PB, Smith CS, Furman MI, Przyklenk K. "Postconditioning" the human heart: multiple balloon inflations during primary angioplasty may confer cardioprotection. Basic Res Cardiol. 2007 ; 102: 274-278
34. Staat P, Rioufol G, Piot C, et al. Postconditioning the human heart. Circulation. 2005 ; 112: 2143-2148
35. Prasad A. Post-conditioning for cardioprotection during reperfusion therapy: too good to be true?. JACC Cardiovasc Interv. 2010 ; 3: 56-57
36. Lonborg J, Holmvang L, Kelbaek H, et al. ST-segment resolution and clinical outcome with ischemic postconditioning and comparison to magnetic resonance. Am Heart J. 2010 ; 160: 1085-1091
37. Eltzschig HK, Eckle T. Ischemia and reperfusion: from mechanism to translation. Nat Med. 2011 ; 17: 1391-1401
38. Eckle T, Eltzschig HK. Toll-like receptor signaling during myocardial ischemia. Anesthesiology. 2011 ; 114: 490-492
39. Wang RP, Yao Q, Xiao YB, et al. Toll-like receptor 4/nuclear factor-kappa B pathway is involved in myocardial injury in a rat chronic stress model. Stress. 2011 ; 14: 567-575
40. Ao L, Zou N, Cleveland JC, Fullerton DA, Meng X. Myocardial TLR4 is a determinant of neutrophil infiltration after global myocardial ischemia: mediating KC and MCP-1 expression induced by extracellular HSC70. Am J Physiol Heart Circ Physiol. 2009 ; 297: H21 - H28
41. Chao W. Toll-like receptor signaling: a critical modulator of cell survival and ischemic injury in the heart. Am J Physiol Heart Circ Physiol. 2009 ; 296: H1 - H12
42. Kats S, Schonberger JP, Brands R, Seinen W, van Oeveren W. Endotoxin release in cardiac surgery with cardiopulmonary bypass: pathophysiology and possible therapeutic strategies-an update. Eur J Cardiothorac Surg. 2011 ; 39: 451-458
43. Faxon DP, Gibbons RJ, Chronos NA, Gurbel PA, Sheehan F. The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT-MI study. J Am Coll Cardiol. 2002 ; 40: 1199-204
44. Eltzschig HK. Adenosine: an old drug newly discovered. Anesthesiology. 2009 ; 111: 904-915
45. Eltzschig HK. Targeting hypoxia-induced Inflammation. Anesthesiology. 2011 ; 114: 239-242
46. Eltzschig HK, Carmeliet P. Hypoxia and inflammation. N Engl J Med. 2011 ; 364: 656-665
47. Eltzschig HK, Collard CD. Vascular ischaemia and reperfusion injury. Br Med Bull. 2004 ; 70: 71-86
48. Hasko G, Linden J, Cronstein B, Pacher P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov. 2008 ; 7: 759-770
49. Eckle T, Krahn T, Grenz A, et al. Cardioprotection by ecto-5′-nucleotidase (CD73) and A2B adenosine receptors. Circulation. 2007 ; 115: 1581-1590
50. Philipp S, Yang XM, Cui L, Davis AM, Downey JM, Cohen MV. Postconditioning protects rabbit hearts through a protein kinase C-adenosine A2b receptor cascade. Cardiovasc Res. 2006 ; 70: 308-314
51. Lopaschuk GD, Stanley WC. Glucose metabolism in the ischemic heart. Circulation. 1997 ; 95: 313-315
52. Lopaschuk GD, McNeil GF, McVeigh JJ. Glucose oxidation is stimulated in reperfused ischemic hearts with the carnitine palmitoyltransferase 1 inhibitor, Etomoxir. Mol Cell Biochem. 1989 ; 88: 175-179
53. Rosano GM, Vitale C, Sposato B, Mercuro G, Fini M. Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study. Cardiovasc Diabetol. 2003 ; 2: 16
54. Grabczewska Z, Bialoszynski T, Szymanski P, et al. The effect of trimetazidine added to maximal anti-ischemic therapy in patients with advanced coronary artery disease. Cardiol J. 2008 ; 15: 344-350
55. Chaitman BR. Efficacy and safety of a metabolic modulator drug in chronic stable angina: review of evidence from clinical trials. J Cardiovasc Pharmacol Ther. 2004 ; 9 (suppl 1). S47 - S64
56. Türel B, Gemici K, Baran I, et al. Effects of glucose-insulin- potassium solution added to reperfusion treatment in acute myocardial infarction. Anadolu Kardiyol Derg. 2005 ; 5: 90-94
57. Kloner RA, Nesto RW. Glucose-insulin-potassium for acute myocardial infarction: continuing controversy over cardioprotection. Circulation. 2008 ; 117: 2523-2533
58. Apstein CS, Opie LH. A challenge to the metabolic approach to myocardial ischaemia. Eur Heart J. 2005 ; 26: 956-959
59. Wang P, Lloyd SG, Chatham JC. Impact of high glucose/high insulin and dichloroacetate treatment on carbohydrate oxidation and functional recovery after low-flow ischemia and reperfusion in the isolated perfused rat heart. Circulation. 2005 ; 111: 2066-2072
60. Cesar LA, Gowdak LH, Mansur AP. The metabolic treatment of patients with coronary artery disease: effects on quality of life and effort angina. Curr Pharm Des. 2009 ; 15: 841-849
61. Durgan DJ, Young ME. The cardiomyocyte circadian clock: emerging roles in health and disease. Circ Res. 2010 ; 106: 647-658
62. Durgan DJ, Young ME. Linking the cardiomyocyte circadian clock to myocardial metabolism. Cardiovasc Drugs Ther. 2008 ; 22: 115-124
63. Durgan DJ, Tsai JY, Grenett MH, et al. Evidence suggesting that the cardiomyocyte circadian clock modulates responsiveness of the heart to hypertrophic stimuli in mice. Chronobiol Int. 2011 ; 28: 187-203
64. Durgan DJ, Trexler NA, Egbejimi O, et al. The circadian clock within the cardiomyocyte is essential for responsiveness of the heart to fatty acids. J Biol Chem. 2006 ; 281: 24254-24269
65. Durgan DJ, Pulinilkunnil T, Villegas-Montoya C, et al. Short communication: ischemia/reperfusion tolerance is time-of-day-dependent: mediation by the cardiomyocyte circadian clock. Circ Res. 2010 ; 106: 546-550
66. Durgan DJ, Hotze MA, Tomlin TM, et al. The intrinsic circadian clock within the cardiomyocyte. Am J Physiol Heart Circ Physiol. 2005 ; 289: H1530 - H1541
67. Bray MS, Shaw CA, Moore MW, et al. Disruption of the circadian clock within the cardiomyocyte influences myocardial contractile function, metabolism, and gene expression. Am J Physiol Heart Circ Physiol. 2008 ; 294: H1036 - H1047
68. Bell-Pedersen D, Cassone VM, Earnest DJ, et al. Circadian rhythms from multiple oscillators: lessons from diverse organisms. Nat Rev Genet. 2005 ; 6: 544-556
69. Hardin PE, Krishnan B, Houl JH, et al. Central and peripheral circadian oscillators in Drosophila. Novartis Found Symp. 2003 ; 253: 140-150
70. Hardin PE. Essential and expendable features of the circadian timekeeping mechanism. Curr Opin Neurobiol. 2006 ; 16: 686-692
71. Hardin PE. The circadian timekeeping system of Drosophila. Curr Biol. 2005 ; 15: R714 - R722
72. Bass J, Takahashi JS. Circadian integration of metabolism and energetics. Science. 2010 ; 330: 1349-1354
73. Marcheva B, Ramsey KM, Buhr ED, et al. Disruption of the clock components CLOCK and BMAL1 leads to hypoinsulinaemia and diabetes. Nature. 2010 ; 466: 627-631
74. Dufour CR, Levasseur MP, Pham NH, et al. Genomic convergence among ERRalpha, PROX1, and BMAL1 in the control of metabolic clock outputs. PLoS Genet. 2011 ; 7: e1002143
75. Monich V, Drugova O, Lazukin V, Bavrina A. Low-power light and isolated rat hearts after ischemia of myocardium. J Photochem Photobiol B. 2011 ; 105: 21-24